1	Comparative analysis of point-of-care lateral flow immunoassays for the detection of IgM and
2	IgG anti-SARS-CoV-2 antibodies in healthcare workers
3	
4	Danielle Dias Conte ¹ , Joseane Mayara Almeida Carvalho ¹ , Luciano Kleber de Souza Luna ^{*1} ,
5	Klinger Soares Faíco-Filho ¹ , Ana Helena Perosa ² , Nancy Bellei ¹ .
6	
7	¹ Department of Medicine, Discipline of infectious diseases, Universidade Federal de São Paulo
8	² Universidade Federal de São Paulo, Hospital São Paulo
9	
10	*Corresponding author: Luciano Kleber de Souza Luna
11	Universidade Federal de São Paulo, Laboratório de Virologia Clínica. Rua Pedro de Toledo, Rua
12	Pedro de Toledo, 781 - Vila Clementino. 04039-032, São Paulo, SP, Brazil. Phone: + 55 11 5576-
13	4848, branch 2222. E-mail: <u>lksluna@gmail.com</u>
14	
15	

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

16 Abstract

17	Since the Coronavirus Disease 2019 (COVID-19) pandemic, Brazil has the third-highest number of
18	confirmed cases and the second-highest number of recovered patients. SARS-CoV-2 detection by
19	real-time RT-PCR is the gold standard in certified infrastructured laboratories. However, for large-
20	scale testing, diagnostics should be fast, cost-effective, widely available, and deployed for the
21	community, such as serological tests based on lateral flow immunoassay (LFIA) for IgM/IgG
22	detection. We evaluated three different commercial point-of-care (POC) LFIAs for anti-SARS-
23	CoV-2 IgM and IgG detection in capillary whole blood of 100 healthcare workers (HCW)
24	previously tested by RT-PCR: 1) COVID-19 IgG/IgM BIO (Bioclin, Brazil), 2) Diagnostic kit for
25	IgM/IgG Antibody to Coronavirus (SARS-CoV-2) (Livzon, China); and 3) SARS-CoV-2 Antibody
26	Test (Wondfo, China). A total of 84 positives and 16 negatives HCW were tested. The data was also
27	analyzed by the number of days after symptoms (DAS) in three groups: <30 (n=26), 30-59 (n=42),
28	and >59 (n=16). Overall detection was 85.71%, 47.62%, and 44.05% for Bioclin, Livzon, and
29	Wondfo, respectively, with a specificity of 100%, and 98.75% for Livzon on storage serum
30	samples. Bioclin was more sensitive (p <0.01), regardless of the DAS. Thus, the Bioclin can be used
31	as a POC test to monitor SARS-CoV-2 seroconversion in HCW.
32	
33	Keywords: SARS-CoV-2 detection, point-of-care, lateral flow immunoassay, healthcare workers.

34

35 **1. Introduction**

After almost seven months since the Coronavirus Disease 2019 (COVID-19) pandemic, caused by de the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Brazil reached, until late August 2020, the second place in the number of confirmed cases. Currently (on September 15, 2020), in the third position, accounts for 4,345,610 confirmed cases, with 132,006 deaths, and is the second country with the highest number of recovered patients (3,770,138) (Dong, Du, and Gardner, 2020).

The molecular detection of SARS-CoV-2 by real-time Reverse Transcription-Polymerase Chain 42 Reaction (RT-PCR) is the gold standard test but requires a certified laboratory infrastructure with 43 high-cost equipment and trained personnel. This structure is suitable, and of paramount importance. 44 for the diagnostic of hospitalized patients, as well as healthcare workers (HCW). However, for 45 46 large-scale testing, RT-PCR is not the best option. Therefore, COVID-19 diagnostic tests should be fast, cost-effective, widely available, and deployed for the community. In general, those requisites 47 are achieved by serological tests based on lateral flow immunoassay (LFIA). Many LFIAs have 48 been described for the detection of IgM and IgG immunoglobulins against SARS-CoV-2 (Vashist, 49 2020). Immunoglobulin response against viral infection begins with an early and transient IgM 50 production, followed by a longer and lasting IgG response. In patients with COVID-19, the 51 production of IgM and IgG could be simultaneous and detected after two days of symptoms onset. 52 and could reach in some patients a plateau level after six days (Long et al., 2020; Zhao et al., 2020). 53 Moreover, the immunoglobulin levels are correlated positively with the severity of COVID-19 54 although the antibody response could be delayed in critical patients compared to non-critical cases 55 (Qu et al., 2020). 56

57 In the present study, we evaluated the sensitivity of three different commercial Point-of-care (POC)

58 LFIAs for anti-SARS-CoV-2 antibody detection, in HCW with confirmed tests (positive or

negative) for COVID-19 by RT-PCR assay.

60

61 **2. Material and methods**

- Three commercial POC LFIAs for detection of anti-SARS-CoV-2 IgG and IgM were tested: 1) 62 COVID-19 IgG/IgM BIO (Bioclin, Brazil), 2) Diagnostic kit for IgM/IgG Antibody to Coronavirus 63 64 (SARS-CoV-2) (Livzon, China); and 3) SARS-CoV-2 Antibody Test (Wondfo, China). Bioclin and Livzon LFIAs independently detect IgG and IgM, whereas Wondfo detects IgG and IgM combined. 65 A total of 100 HCW from University Hospital São Paulo, previously tested for SARS-CoV-2 66 infection by real-time RT-PCR, were enrolled in the study. From them, 84 were confirmed positive, 67 and 16, negative. Furthermore, 80 storage serum samples, collected during 2018 and 2019, were 68 also tested with Livzon LFIA, the only test available for this additional analysis. 69 The indicated volume of capillary whole blood for each test, collected preferably from the skin of 70 annular fingertip with a lancing device, was added immediately into the cassette sample wells, 71 72 following the addition of sample diluent according to the manufacturer instructions. All LFIAs were tested simultaneously in the moment of blood draw of each investigated HCW. Similarly, the 73 recommended serum volume for testing the 80 storage serum samples with Livzon LFIA was also 74 applied accordingly. Results were read within 1-15 minutes. 75 Sensitivity was calculated as the proportion of positive results of LFIAs in relation to the positive 76 RT-PCR confirmed cases, and specificity was calculated as the proportion of LFIAs negative results 77 in relation to the negative RT-PCRs. The 95% confidence intervals (CI) of sensitivity and 78 specificity proportions were calculated by the modified Wald method. The results were also 79 analyzed according to the number of days after symptoms (DAS), distributed in three distinct 80 groups: <30 (n=26), 30-59 (n=42), and >59 (n=16). The proportion of results accounted for IgM 81 and IgG, alone or combined, regarding DAS, and pairwise comparison within LIFAs was analyzed 82 83 by Cochran's Q and McNemar tests, for a *p*-value <0.05. The analysis was made using software R version 4.0.2 (Team, 2020). 84 The study was approved by the São Paulo hospital Research Ethics Committee (CEP n. 85
 - 86 34371020.5.0000.5505).

87 **3. Results**

- 88 The age of investigated HCWs varied from 20 to 67 yeas (mean = 37.45, median = 36). Overall
- 89 detection of IgM and IgG, individually or combined, are described in table 1.
- 90
- 91 **Table 1:** Comparison of LFIAs results with 84 positive RT-PCR for SARS-CoV-2.

	I FIA	number / Sensitivity in % (95% CI)					
	LITA	IgG/IgM	IgM	IgG			
	Bioclin	72 / 85.71 (76.52-91.79)	46 / 54.76 (44.14-64.97)	72 / 85.71 (76.52-91.79)			
	Livzon	40 / 47.62 (37.28-58.17)	25 / 29.76 (21.01-40.29)	54 / 35.71 (26.28-46.40)			
	Wondfo	37 / 44.05 (33.92-54.70)	N.A.	N.A.			
92	N.A., not av	vailable.					
93							
94	In general, Bioclin LFIA showed the highest sensitivity (85.71%), followed by Livzon (47.62%)						
95	and Wondfo (44.05%).						
96	In comparison to the 16 negative RT-PCR individuals, the sensitivity of all LFIAs was 100%						
97	(77.31% to	100%, 95% CI). However, or	ne storage serum sample from	2018 was IgG reagent by			
98	Livizon LF	IA and therefore the sensitivi	ty of this additional test was 9	8.75% (92.59% to 99.99%,			
99	95% CI).						
100	The results	according to the groups of D.	AS (<30, 30-59, and >59), are	e depicted in table 2.			
101							
102							
103							
104							
105							
106							
107							
108							
109							

Antibody	DAS	HCW	number (%)			n valor
Antibody	DAS	IIC W	Bioclin	Wondfo	Livzon	p-valor
IgM/IgG ¹	<30	26	22 (88.00)	14 (56.00)	13 (52.00)	0.0022*
	30-59	42	38 (88.37)	21 (48.84)	17 (39.53)	<0.001*
	>59	16	12 (75.00)	5 (31.25)	7 (43.75)	0.0131*
IgM ²	<30	26	19 (76.00)	NA	11 (44.00)	0.0047*
	30-59	42	21 (48.84)	NA	11 (25.58)	0.03892*
	>59	16	6 (37.50)	NA	3 (18.75)	0.0833
IgG ²	<30	26	22 (88.00)	NA	10 (44.00)	0.0005*
	30-59	42	38 (88.37)	NA	15 (34.88)	<0.001*
	>59	16	12 (75.00)	NA	5 (31.25)	0.0081

110 Table 2: Comparison of LFIAs results in time groups according to the days after symptoms (DAS).

DAS, days after symptoms. HCW, healthcare workers. 111

* significant for p<0.05 112

¹Cochran's Q test, p<0.05 113

²McNemar test, p<0.05 114

115

The Bioclin LFIA was significantly more sensitive, in comparison to Livzon and Wondfo, 116

regardless of the DAS or detection of IgM and IgG combined (Cochran's Q test, p < 0.05). The 117

posthoc analysis of pairwise comparisons with McNemar tests also have shown that Bioclin was 118

more sensitive than Livzon and Wondfo for IgM and IgG individually, and no differences were 119

observed between Livzon and Wondfo regardless of the DAS or immunoglobulin class (table 2). 120

121 The proportion of positives within each LFIA in relation to the DAS have shown any significant

difference for overall IgM and IgG detection (Bioclin, p=0.316; Livzon, p=0.744; Wondfo, p=0.33), 122

123 IgG alone (Bioclin,
$$p=0.316$$
; Livzon, $p=0.894$), or IgM (Bioclin, $p=0.054$; Livzon, $p=0.208$),

- although Bioclin is likely to be more sensitive for IgM in the group of <30 (p=0.054). 124
- 125
- 126
- 127
- 128
- 129

130 **4. Discussion**

131	In the present study, we analyzed three different commercial LFIAs for the detection of anti-SARS-
132	CoV-2 IgG and IgM in HCW. For the POC test format, capillary whole blood is more suitable than
133	serum or plasma and does not require a laboratory infrastructure for venous blood draw.
134	The use of POC based tests for rapid antibody detection can be helpful in identifying patients at
135	different stages of infection, due to the early production of IgM followed by IgG response, even
136	though in patients with COVID-19 the IgM and IgG response could be simultaneous. Our results
137	demonstrated that overall sensitivity achieved by Bioclin LFIA (85.71%) with whole blood samples
138	is compared to those obtained with serum or plasma, in contrast to Livzon and Wondfo LFIAs
139	which showed sensitivities below 50% (Costa et al., 2020; Santos et al., 2020; Silveira et al., 2020;
140	Tuaillon et al., 2020).
141	Similar to the results here described, Santos et al. (2020) have shown, for capillary whole blood, a
142	sensitivity of 55% for the Wondfo LFIA test in HCWs. On the other hand, the detection sensitivity
143	in serum samples was much higher (96%). In a larger study with hospitalized patients, Costa et al.
144	(2020) evaluated the Wondfo LFIA, in serum samples or plasma, and obtained a sensitivity of
145	85.8%. In another evaluation of the Wondfo LFIA, Wu et al. (2020) have shown a sensibility of
146	75.8% in serum samples. In the same manner, Livzon LFIA, when tested in serum samples of
147	hospitalized patients, presented a sensibility of 80% for IgM and 86.7 for IgG, with a specificity of
148	95% and 100% respectively.
149	An advantage of the present study is due to the fact that all LFIAs were carried out simultaneously

at the time of blood draw from each HCW. On the other hand, a limitation of the study was the
impossibility of follow up on each HCW to observe possible variations in the detection of IgM and
IgG over time, or to expand the study to include hospitalized patients or low-income individuals
from the general community.

154

155

156 **5. Conclusion**

157	Bioclin LFIA demonstrated high sensitivity and specificity for IgG detection (85.71%), and a
158	reasonable detection of IgM (54.76%), with the use of capillary whole blood in HCW. On the other
159	hand, Livzon and Wondfo LFIAs presented overall sensitivity below 50%. Thus, the Bioclin LFIA
160	is a suitable POC test to monitor SARS-CoV-2 seroconversion in HCW.
161	
162	Acknowledgments
163	J.M.A.C. and L.K.S.L. are fellows of the Coordenação de Aperfeiçoamento de Pessoal deNível
164	Superior (CAPES), Brazil. D.D.C. is a fellow of the Conselho Nacional de Desenvolvimento
165	Científico e Tecnológico (CNPq), Brazil. We are grateful to Anderson Scorsato for the statistical
166	support.
167	
168	Declarations of interest: none
169	
170	CRediT authorship contribution statement
171	Danielle D. Conte: Validation, Investigation, Data Curation, Writing - Original Draft. Joseane M.
172	A. Carvalho: Investigation, Data Curation. Luciano K. de Souza Luna: Validation, Investigation,
173	Formal analysis, Writing - Review & Editing, Visualization. Klinger S. Faíco-Filho: Investigation.
174	Ana H. S. Perosa: Investigation. Nancy Bellei: Conceptualization, Methodology, Resources,
175	Supervision, Writing - Review & Editing, Project administration, Funding acquisition.
176	
177	
178	
179	
180	
181	

medRxiv preprint doi: https://doi.org/10.1101/2020.11.11.20229914; this version posted November 12, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

182 **References**

- Costa, S.F., Buss, L., Espinoza, E.P.S., Vieira, J.M., Jr., de Oliveira da Silva, L.C., de Souza, R.M., Neto, L.P., Porto,
 A.P.M., Lazari, C., Dos Santos, V.A., da Silva Duarte, A., Nastri, A.C., da Costa Leite, G.F., Manuli, E.,
 de Oliveira, M.S., Zampelli, D.B., Pastore, L.J., Segurado, A.C., Levin, A.S. and Sabino, E., 2020.
 Performance of a qualitative rapid chromatographic immunoassay to diagnose COVID-19 in patients
 in a middle-income country. J Clin Virol 131, 104592.
- Dong, E., Du, H. and Gardner, L., 2020. An interactive web-based dashboard to track COVID-19 in real time.
 Lancet Infect Dis 20, 533-534.
- Long, Q.X., Liu, B.Z., Deng, H.J., Wu, G.C., Deng, K., Chen, Y.K., Liao, P., Qiu, J.F., Lin, Y., Cai, X.F., Wang, D.Q.,
 Hu, Y., Ren, J.H., Tang, N., Xu, Y.Y., Yu, L.H., Mo, Z., Gong, F., Zhang, X.L., Tian, W.G., Hu, L., Zhang,
 X.X., Xiang, J.L., Du, H.X., Liu, H.W., Lang, C.H., Luo, X.H., Wu, S.B., Cui, X.P., Zhou, Z., Zhu, M.M.,
 Wang, J., Xue, C.J., Li, X.F., Wang, L., Li, Z.J., Wang, K., Niu, C.C., Yang, Q.J., Tang, X.J., Zhang, Y., Liu,
 X.M., Li, J.J., Zhang, D.C., Zhang, F., Liu, P., Yuan, J., Li, Q., Hu, J.L., Chen, J. and Huang, A.L., 2020.
 Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med 26, 845-848.
- Qu, J., Wu, C., Li, X., Zhang, G., Jiang, Z., Li, X., Zhu, Q. and Liu, L., 2020. Profile of IgG and IgM antibodies
 against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis.
- Santos, V.A.D., Rafael, M.M., Sabino, E.C. and Duarte, A., 2020. Sensitivity of the Wondfo One Step COVID-19
 test using serum samples. Clinics (Sao Paulo) 75, e2013.
- Silveira, M.F., Barros, A.J.D., Horta, B.L., Pellanda, L.C., Victora, G.D., Dellagostin, O.A., Struchiner, C.J.,
 Burattini, M.N., Valim, A.R.M., Berlezi, E.M., Mesa, J.M., Ikeda, M.L.R., Mesenburg, M.A., Mantesso,
 M., Dall'Agnol, M.M., Bittencourt, R.A., Hartwig, F.P., Menezes, A.M.B., Barros, F.C., Hallal, P.C. and
 Victora, C.G., 2020. Population-based surveys of antibodies against SARS-CoV-2 in Southern Brazil.
 Nat Med 26, 1196-1199.
- Team, R.C. 2020. R: A Language and Environment for Statistical Computing, R Foundation for Statistical
 Computing, Vienna, Austria.
- Tuaillon, E., Bollore, K., Pisoni, A., Debiesse, S., Renault, C., Marie, S., Groc, S., Niels, C., Pansu, N., Dupuy,
 A.M., Morquin, D., Foulongne, V., Bourdin, A., Le Moing, V. and Van de Perre, P., 2020. Detection of
 SARS-CoV-2 antibodies using commercial assays and seroconversion patterns in hospitalized
 patients. J Infect 81, e39-e45.
- Vashist, S.K., 2020. In Vitro Diagnostic Assays for COVID-19: Recent Advances and Emerging Trends.
 Diagnostics (Basel) 10.
- Wu, J.L., Tseng, W.P., Lin, C.H., Lee, T.F., Chung, M.Y., Huang, C.H., Chen, S.Y., Hsueh, P.R. and Chen, S.C.,
 2020. Four point-of-care lateral flow immunoassays for diagnosis of COVID-19 and for assessing
 dynamics of antibody responses to SARS-CoV-2. J Infect.
- Zhao, J., Yuan, Q., Wang, H., Liu, W., Liao, X., Su, Y., Wang, X., Yuan, J., Li, T., Li, J., Qian, S., Hong, C., Wang,
 F., Liu, Y., Wang, Z., He, Q., Li, Z., He, B., Zhang, T., Fu, Y., Ge, S., Liu, L., Zhang, J., Xia, N. and Zhang,
 Z., 2020. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect
 Dis.